OSTEOSARCOMA RTU

EFFICACY AND SAFETY ASSESSMENT OF BIOCERA-VET CEMENTOPLASTY

• Prospective, non-controlled clinical trial
• Multicentric (6 sites in France)
• 12 dogs of medium, large and giant-sized breeds suffering from an appendicular osteosarcoma
• Percutaneous cementoplasty with BIOCERA-VET¹. No other treatment than cementoplasty: no radiotherapy and no chemotherapy

Efficacy on pain (% of dogs with ≥ 50% score reduction vs score at baseline)

• Pain evaluation by owner (VAS): 67% of dogs at 1 month & 50% at 2 and 6 months with ≥ 50% score reduction vs score at baseline.
• Pain interference with function (PIS): 33% of dogs at 1 month & 50% at 2 months with ≥ 50% score reduction vs score at baseline.
• Pain severity (PSS): 56% of dogs at 1 month & 50% at 2 months with ≥ 50% score reduction vs score at baseline.

Quality of Life (QoL) owner evaluation

• QoL score: Improvement in 78% of dogs at 1 month & 50% at 2 and 6 months.

Safety

• 25% of complications were reported after the percutaneous BIOCERA-VET cementoplasty (compared to a 75% rate for a similar approach of cementoplasty performed with PMMA²).
• One fracture reported (8%) (compared to a 40% incidence of fractures in canine osteosarcoma³).

BIOCERA-VET^® – efficacy and safety assessment of cementoplasty in dogs with Osteosarcoma (Nov 2021). NRS: Numerical Rating Score; PMMA: Polymethyl methacrylate ⁽¹⁾ Clinical study was performed with OSTEOSARCOMA 8cc version ⁽²⁾ Böttcher P et al., Percutaneous cementoplasty in the palliative, multimodal treatment of primary bone tumors of the distal aspect of the radius in four dogs. Vet Surg. 2009 Oct;38(7):888-901. ⁽³⁾ Rubin J et al., Factors associated with pathological fractures in dogs with appendicular primary bone neoplasia: 84 cases ( 2007-2013 ). J Am Vet Med Assoc. 2015 Oct 15;247(8):917-23.